Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

6    Eli Lilly    $14.9B    up 4.2%
Global revenue: $24.3B (10th); up 5.2%

R&D spend: $5.0B (9th), up 2.0%; 20.6% of rev.

Top brands: Cymbalta ($3.2B), Zyprexa ($2.2B), Humalog ($1.4B), Alimta ($995M), Evista ($707M)

Planned launches: BI 10773 (diab.), dulaglutide (diab.)

Promotional spend: $1.4B (2nd); 9.2% of rev.

Patent expirations: Humalog (2013), Cymbalta (2014), Evista (2014)

Eli Lilly spends the most of the top 20 drugmakers, as a percentage of revenue, on R&D. Unfortunately, R&D output is not necessarily correlated with what you spend, showed a study funded by the Midwest company which was cited by the Sanford Bernstein analyst Tim Anderson. Anderson predicts a bolt-on acquisition. But Lilly's pipeline is slowly improving. After its GLP-1 partnership with Amylin dissolved late last year, dulaglutide moved to the forefront as its lead GLP-1 candidate, and Lilly is aiming for a 2013 filing. Somewhat of a longshot is Alzheimer's candidate solanezumab, which passed an interim safety analysis in January. Recent  launch Tradjenta was the third DPP-IV to market and has diabetes giant Januvia to contend with. Patent expirations loom on two megablockbusters—CNS drug Cymbalta and diabetes med Humalog.

Back to first page

Page 6 of 21
Share this article:

Email Newsletters

More in Features

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Private View: Discussing Women's Health

Private View: Discussing Women's Health

Dan Chichester, chief creative officer, LLNS